Switch theme
Sign up to access all valuation multiples
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
2016
160
LTM Revenue $83.2M
LTM EBITDA -$62.7M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ARS Pharmaceuticals has a last 12-month revenue (LTM) of $83.2M and a last 12-month EBITDA of -$62.7M.
In the most recent fiscal year, ARS Pharmaceuticals achieved revenue of $89.1M and an EBITDA of -$3.1M.
ARS Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ARS Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $83.2M | XXX | $89.1M | XXX | XXX | XXX |
| Gross Profit | $78.1M | XXX | $88.2M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | -$62.7M | XXX | -$3.1M | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -3% | XXX | XXX | XXX |
| EBIT | -$67.5M | XXX | -$3.1M | XXX | XXX | XXX |
| EBIT Margin | -81% | XXX | -3% | XXX | XXX | XXX |
| Net Profit | -$57.0M | XXX | $8.0M | XXX | XXX | XXX |
| Net Margin | -68% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ARS Pharmaceuticals's stock price is $14.
ARS Pharmaceuticals has current market cap of $1.4B, and EV of $1.1B.
See ARS Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.4B | XXX | XXX | XXX | XXX | $-0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ARS Pharmaceuticals has market cap of $1.4B and EV of $1.1B.
ARS Pharmaceuticals's trades at 12.8x EV/Revenue multiple, and -370.0x EV/EBITDA.
Equity research analysts estimate ARS Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ARS Pharmaceuticals has a P/E ratio of -24.9x.
See valuation multiples for ARS Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 13.7x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | -18.2x | XXX | -370.0x | XXX | XXX | XXX |
| EV/EBIT | -16.9x | XXX | -370.0x | XXX | XXX | XXX |
| EV/Gross Profit | 14.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -24.9x | XXX | 177.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 87.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialARS Pharmaceuticals's last 12 month revenue growth is 52%
ARS Pharmaceuticals's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.6M for the same period.
ARS Pharmaceuticals's rule of 40 is -225015% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ARS Pharmaceuticals's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ARS Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 52% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -225015% | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 102% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ARS Pharmaceuticals acquired XXX companies to date.
Last acquisition by ARS Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . ARS Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ARS Pharmaceuticals founded? | ARS Pharmaceuticals was founded in 2016. |
| Where is ARS Pharmaceuticals headquartered? | ARS Pharmaceuticals is headquartered in United States of America. |
| How many employees does ARS Pharmaceuticals have? | As of today, ARS Pharmaceuticals has 160 employees. |
| Who is the CEO of ARS Pharmaceuticals? | ARS Pharmaceuticals's CEO is Mr. Richard E. Lowenthal, M.B.A.,M.S.. |
| Is ARS Pharmaceuticals publicy listed? | Yes, ARS Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of ARS Pharmaceuticals? | ARS Pharmaceuticals trades under SPRY ticker. |
| When did ARS Pharmaceuticals go public? | ARS Pharmaceuticals went public in 2022. |
| Who are competitors of ARS Pharmaceuticals? | Similar companies to ARS Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ARS Pharmaceuticals? | ARS Pharmaceuticals's current market cap is $1.4B |
| What is the current revenue of ARS Pharmaceuticals? | ARS Pharmaceuticals's last 12 months revenue is $83.2M. |
| What is the current revenue growth of ARS Pharmaceuticals? | ARS Pharmaceuticals revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of ARS Pharmaceuticals? | Current revenue multiple of ARS Pharmaceuticals is 13.7x. |
| Is ARS Pharmaceuticals profitable? | Yes, ARS Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ARS Pharmaceuticals? | ARS Pharmaceuticals's last 12 months EBITDA is -$62.7M. |
| What is ARS Pharmaceuticals's EBITDA margin? | ARS Pharmaceuticals's last 12 months EBITDA margin is -75%. |
| What is the current EV/EBITDA multiple of ARS Pharmaceuticals? | Current EBITDA multiple of ARS Pharmaceuticals is -18.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
